no association of dose of non-purine-like XOI with incidence of TCE and SAE. Significant statistical heterogeneity was not observed in any test reported here.
The tendon thickness decreased over time no matter of symptoms and had no impact on the prognosis, neither did heel spur. Only 24% of the asymptomatic participants had a normal tendon on ultrasound at long-term follow-up. Ultrasound guided steroid injection did not give atrophy of the heel fat pad in long-term follow-up. Rheumatology, Neuchatel Hospital, Neuchatel; 3 Orthopaedics and Traumatology, Geneva University Hospital, Geneva, Switzerland Background: Although small observational studies have suggested that local corticosteroid (CS) injection may be effective in the management of the greater trochanteric pain syndrome (GTPS), no prospective placebo controlled study has been carried out to establish the efficacy of this common intervention. Objectives: To perform a randomized double-blind placebo controlled trial to investigate the efficacy of local CS injection in the management of GTPS. Methods: The trial was conducted in the Rheumatology unit of a University teaching hospital in Geneva, Switzerland. Inclusion criteria were lateral hip pain (LHP) for greater than 1 month, a LHP score of ≥4 in the preceding week, failure of another standard treatment (physiotherapy, analgesics, etc.) and typical LHP reproduced by palpation of the greater trochanter (GT). Participants were randomised in a 1:1 ratio to: 1) injection with a combination of local anaesthetic and CS (Treatment group), or 2) injection with normal saline solution (Placebo group). The Treatment group received 4ml of 1% Lidocaine (Rapidocain ® ) and 1ml of Bethametasone (Diprophos ® ). The Placebo group received 5ml of sterile saline solution. Injections were performed under ultrasound guidance. The study's predefined primary outcome of interest was the difference in pain intensity at 4 weeks post-injection between the 2 groups. Secondary outcomes included the number of "responders" (pain score improvement of ≥1.5) and the number of patients with low disease activity (LDA) (pain score ≤2.0). Patients were followed up for 6 months. Results: A total of 46 patients were included and there were no significant differences between the 2 groups at baseline (Table 1 ). There were no significant differences between the 2 groups in terms of the reduction in pain at one month post-injection, with scores of -1.5 and -2.5 (p=0.23) in the Treatment and Placebo groups respectively. When including all measures in the first 3 weeks and using multilevel regression, there was a marginally significant improvement in pain scores in favour of the Treatment group (p=0.08) (Figure 1 ). There were no significant differences in terms of the percentage of responders (p=0.32), or patients with LDA (p=0.50) between the 2 groups at follow up. There were no significant differences in pain scores between groups at 3 and 6 months post-injection.
Conclusions:
Local corticosteroid injection in the management of GTPS is only marginally effective for a few weeks. Given the lack of long-term improvement and the potential for cortisone-related side-effects, this intervention is of limited benefit. Background: Low back pain (LBP) is associated with 2.3, 2.2, and 1.6 times greater odds for mood disorders, anxiety disorders and alcohol abuse respectively (1). Continued anxiety may lead to a state of "learned helplessness", and both can propagate in a vicious cycle. Glucosamine-chondroitin sulfate (GCS) combination is widely used in the treatment of OA; however there are few prospective studies of its therapeutic merits in LBP. Objectives: To study the efficacy of GCS in the decreasing anxiety in patients with chronic LBP in a large open pilot prospective study.
Methods:
We enrolled patients 40 -65 years of age who had LBP for >12 weeks with pain intensity >3 on a 0-10 point VAS in a single-arm, open-label prospective interventional study. Major exclusion criteria were the presence of fibromyalgia, spondylolisthesis, and alcohol and/or drug abuse. All patients were treated with ARTRA (combination glucosamine hydrochloride 500 mg -chondroitin sulfate 500 mg in tablet form; Unipharm Inc.) at a dose of 1 tab bid for the first month and then 1 tab daily for the next two months. The primary endpoint was pain intensity as measured on a 0-10 point VAS. Secondary endpoints included anxiety levels measured by Spielberger's State Trait Anxiety Inventory (STAI) adapted for Russia by Khanin (2). STAI evaluates the current "state" of anxiety, asking how respondents feel "right now," using items that measure subjective feelings of apprehension, tension, nervousness, worry, and activation/arousal of the autonomic nervous system as well as aspects of "anxiety proneness," including general states of calmness, confidence, and security ("trait"). Scores for each scale range from 20 to 80, with higher scores indicating greater anxiety. Results: A total of 8,598 subjects (mean age 52.1 years, 67.3% women, mean BMI 27.4) were enrolled in the study, and formed the intent-to-treat (ITT) population. All but 95 subjects (1.1%) completed the study. Previously-reported ITT analysis with worst observation carried forward showed an improvement in pain at rest from mean (± SD) of 5.2±1.9 at study entry to 1.4±1.6 at 3 months (p<0.0001). Pain at movement decreased from 6.8±1.6 to 2.2±1.8 (p<0.0001).
There was a strong correlation between increasing baseline STAI scores and baseline pain at rest and movement (both p<0.0001). After 12 weeks of GCS treatment, STAI "state" anxiety scores dropped from 49.3 (95% CI 49.1 to 49.6) to 35.8 (95% CI 35.6 -36.0) (p<0.0001). A similar reduction was seen in "trait" anxiety scores from 48.3 (95% CI 48.0-48.5) to 39.6 (95% CI 39.3-39.8) (p<0.001).
Conclusions:
Although open and uncontrolled, this large pilot community-based study shows dramatic reductions in pain and anxiety (both "state" and "trait") in patients with LBP treated with GCS. With its benign safety profile, GCS therapy deserves serious evaluation in the management of LBP in a prospective randomized double-blinded clinical trial. Time to treatment discontinuation, defined as a gap of ≥120 days in medication supply days, and proportion of days covered (PDC) with FM-specific therapies during one year from the first dispense were analyzed. Multivariable logistic regression models were constructed to analyze factors associated with low (PDC <20%) and high (PDC ≥80%) adherence. Results: Overall 3932 eligible FM patients were identified, 88.7% females, mean) SD (age =49.2 (12.7). Pre-diagnosis use of medications of interest was documented in 41% of the patients. Of the remaining 2312, 56.1% were issued a prescription in the year following diagnosis and 45.0% dispensed at least on medication. One-year discontinuation reached 79.3% overall, and was highest for tricyclic antidepressants and lowest for SSRI/SNRI antidepressants (Table 1) . Over one half of the patients (60.5%) were poorly adherent (PDC<20%) during the year and only 9.3% were highly adherent (PDC≥80%). Low adherence was less prevalent among patients diagnosed with migraines (OR=0.62, 95% CI: 0.48-0.80) or with both depression and anxiety (OR=0.55; 0.40-0.76). High adherence was positively associated with socio-economic status (p-for-trend=0.022). Table 1 . Medications prescribed and dispensed in the first year from diagnosis, proportion discontinuing and time to discontinuation in the year following first dispense (N=1296) Drug group Prescribed ≥1 dispense Discontinued N (%) N (%)* N (%)** Days to discontinuation Median (IQR)
